Regulus Therapeutics (RGLS) Bullish Stance Reiterated at BMO Capital Following EASL Abstract for RG-101

BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $36 price target on Regulus Therapeutics (NASDAQ: RGLS) after , late breaking abstract titles were released for the European Association for the Study of the Liver, EASL meeting were released and include data for RGLS's RG-101.

Birchenough notes, " A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a galnac-conjugated oligonucleotide with antagonist activity against miR-122 results in significant viral load reductions in chronic hepatitis C."

He commented, "We are reiterating our Outperform rating on shares of RGLS following review of EASL abstract for RG-101. We continue to view a broad opportunity to shorten and simplify HCV therapy, address patients with treatment failure and provide a novel option for difficult to treat patients with HCV. Value of pan-genotypic activity with non-overlapping mechanism with existing options has been under-estimated and we continue to see significant value in RG-101."

For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.

Shares of Regulus Therapeutics closed at $19.13 yesterday.

You May Also Be Interested In

• Northwest Bancshares, Inc. (NWBI) PT Lowered to $10 at Piper Sandler
• United Microelectronics Corp (2303:TT) (UMC) PT Lowered to NT$47 at HSBC
• Altice-USA (ATUS) PT Lowered to $2 at Loop Capital